Evonik's Silicone Expansion and Restructuring Costs Pull Analysts in Opposite Directions

Evonik has fired up a new specialty silicones plant in Essen, a roughly €52 million investment that the company says will cut transport volumes across its international production network and head off supply bottlenecks. The facility, which includes tank storage and came on stream yesterday, serves a product range spanning insulation, mattresses and car seats as well as adhesives, coatings, paints and cosmetics. Yet the operational milestone landed alongside a pair of cautious analyst notes and fresh detail on the cost of the group's overhaul, leaving investors to weigh efficiency gains against the cash that restructuring will consume.

Two Houses, Two Reasons to Stay on the Sidelines

JPMorgan kept its "Underweight" rating on the stock even as it lifted its price target. Analyst Udeshi expects free cash flow to fall noticeably in the 2027/28 financial year as restructuring charges bite, and she flagged that both revenue growth and adjusted EBITDA came in slightly below consensus. The higher target, in her view, is no shift toward a positive recommendation — the anticipated drain on funds remains the deciding factor. That cash-flow warning is a forecast for the years ahead, not a decline already on the books.

Deutsche Bank Research struck a similar note of restraint from a different angle. Virginie Boucher-Ferte reaffirmed "Hold" with an €18 price target, noting that quarterly results landed 1% under consensus estimates and that the midpoint of the full-year operating profit guidance range sits slightly below market expectations. Neither house sees reason to turn buyer despite the strong earnings growth; one points to future outflows, the other to the gap versus forecasts.

Provisions Are Not Yet Cash Out the Door

The figures published today already carry the imprint of the savings programme. Evonik booked €313 million in provisions in the third quarter of 2026 and posted a group net loss of €53 million. Provisions and actual disbursements are not the same thing, which is why the timing of the restructuring's financial fallout matters as much as the adjusted result itself — and why JPMorgan's caution is trained squarely on later burdens.

Against that stands a free cash flow that has so far moved in the right direction: €369 million in the third quarter of 2026, up from €300 million a year earlier.

Portfolio Trimming Runs Alongside the Build-Out

The Essen expansion sits within a broader reshaping. Evonik has extended its ETM programme through 2029 and is pressing ahead with the sale of Oxeno, with a buyer expected in the coming months; preparations for a Syneqt divestment have also begun. On the cost side, the group plans to shed 3,200 jobs worldwide by 2029 — so the new plant is no counterweight to the austerity drive. Investment at a central production site and group-wide cost cuts are running in parallel.

Interim chief Claus Rettig restated the standalone ambition yesterday, saying Evonik is conducting no takeover talks with BASF while remaining open to a confidential exchange of information that is purely informational.

The Yardstick Is Return on Capital

Management has set a return on capital employed target of 11% by 2029, against 6.1% in 2025 — a gap that demands substantial improvement. Whether the Essen project earns its place therefore hinges on whether the promised operational benefits show up on the ground; the investment sum alone says nothing about its contribution to earnings. The intended payoff is meant to come from smoother production and transport flows, and the plant makes the standalone strategy more tangible without proving that the return targets are within reach. Site investment, portfolio changes and savings will have to work together for that.